Adial Pharmaceuticals Stock Performance
| ADIL Stock | USD 0.40 0.03 8.11% |
On a scale of 0 to 100, Adial Pharmaceuticals holds a performance score of 6. The firm shows a Beta (market volatility) of 1.59, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Adial Pharmaceuticals will likely underperform. Please check Adial Pharmaceuticals' semi variance, day typical price, and the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether Adial Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Adial Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain forward indicators, Adial Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:25 | Last Split Date 2023-08-07 |
1 | What drives Adial Pharmaceuticals Inc. stock price - Breakthrough stock performance - PrintWeekIndia | 07/25/2025 |
2 | Adial Pharmaceuticals reports Q2 results | 08/14/2025 |
3 | Senate Committee Votes 26-3 to Support Expanded Drug Trial Metrics Adials AUD Treatment Strategy Validated - Stock Titan | 08/20/2025 |
4 | Combining machine learning predictions for Adial Pharmaceuticals Inc. - Weekly Risk Summary Weekly High Potential Stock Alerts - Newser | 08/28/2025 |
5 | Whats the fair value of Adial Pharmaceuticals Inc. stock - Trend Reversal Safe Entry Zone Tips - khodrobank.com | 09/04/2025 |
6 | Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 Meeting for AD04 | 09/16/2025 |
7 | Adial Pharmaceuticals Rating Increased to Buy at Maxim Group | 10/03/2025 |
| Begin Period Cash Flow | 2.8 M |
Adial Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 32.00 in Adial Pharmaceuticals on July 8, 2025 and sell it today you would earn a total of 8.00 from holding Adial Pharmaceuticals or generate 25.0% return on investment over 90 days. Adial Pharmaceuticals is currently generating 0.5714% in daily expected returns and assumes 6.8453% risk (volatility on return distribution) over the 90 days horizon. In different words, 61% of stocks are less volatile than Adial, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Adial Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adial Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Adial Pharmaceuticals, and traders can use it to determine the average amount a Adial Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0835
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ADIL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.85 actual daily | 61 61% of assets are less volatile |
Expected Return
| 0.57 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Adial Pharmaceuticals is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Adial Pharmaceuticals by adding it to a well-diversified portfolio.
Adial Pharmaceuticals Fundamentals Growth
Adial Stock prices reflect investors' perceptions of the future prospects and financial health of Adial Pharmaceuticals, and Adial Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adial Stock performance.
| Return On Equity | -1.71 | ||||
| Return On Asset | -0.88 | ||||
| Current Valuation | 2.86 M | ||||
| Shares Outstanding | 21.83 M | ||||
| Price To Earning | (1.88) X | ||||
| Price To Book | 1.57 X | ||||
| EBITDA | (13.2 M) | ||||
| Net Income | (13.2 M) | ||||
| Cash And Equivalents | 9.16 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 975.86 K | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 5.32 X | ||||
| Book Value Per Share | 0.26 X | ||||
| Cash Flow From Operations | (6.92 M) | ||||
| Earnings Per Share | (0.71) X | ||||
| Market Capitalization | 8.7 M | ||||
| Total Asset | 5.04 M | ||||
| Retained Earnings | (82 M) | ||||
| Working Capital | 3.08 M | ||||
| Current Asset | 1.02 M | ||||
| Current Liabilities | 452.53 K | ||||
About Adial Pharmaceuticals Performance
By examining Adial Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Adial Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Adial Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.62) | (2.75) | |
| Return On Capital Employed | (2.04) | (2.14) | |
| Return On Assets | (2.62) | (2.75) | |
| Return On Equity | (3.24) | (3.41) |
Things to note about Adial Pharmaceuticals performance evaluation
Checking the ongoing alerts about Adial Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adial Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adial Pharmaceuticals is way too risky over 90 days horizon | |
| Adial Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Adial Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Adial Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (13.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Adial Pharmaceuticals currently holds about 9.16 M in cash with (6.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35. | |
| Adial Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Adial Pharmaceuticals Rating Increased to Buy at Maxim Group |
- Analyzing Adial Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adial Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Adial Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adial Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adial Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adial Pharmaceuticals' stock. These opinions can provide insight into Adial Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.